Verimatrix Launches XTD Velocity Partner Alliance to Accelerate Global Channel Sales
19.3.2025 17:45:00 CET | Business Wire | Press release
Risk Associates, a Middle East leader, joins the partner program to drive Verimatrix XTD app protection, threat detection & Response managed services to their customers
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of the Verimatrix XTD Velocity Partner Alliance, a global channel sales program designed to empower partners with best-in-class application protection solutions. As part of this initiative, Risk Associates, a leading Managed Security Services Provider (MSSP), has joined the program to offer Verimatrix XTD Enterprise Suite to banks and enterprises across Australia, Bahrain, Saudi Arabia, and the UAE.
The XTD Velocity Partner Alliance, spearheaded by Simon Emery, Global Head of Strategic Partnerships at Verimatrix, provides resellers, MSSPs, system integrators, and cybersecurity firms with comprehensive resources to deliver AI-powered mobile app shielding, endpoint threat detection, and response solutions. The program enhances channel sales by offering:
- Resell XTD & Deliver Managed Services – Offer 24/7 app hardening with AI-driven threat detection to stop cyberattacks.
- Expert Training & Certification – Gain the skills to deploy and integrate Verimatrix XTD with confidence.
- Marketing & Sales Power – Access co-branded campaigns, deal registration, and exclusive marketing funds.
- Innovate & Collaborate – Partner on cutting-edge security solutions through joint development and certification.
“With the Verimatrix XTD Velocity Partner Alliance, we're redefining how cybersecurity providers and channel partners collaborate to accelerate app protection at scale,” said Jon Samsel, Global Head of Cybersecurity Business at Verimatrix. “Our expanded partnership with Risk Associates has already resulted in six banks choosing Verimatrix to safeguard their applications—and we’re just getting started. Strategic alliances like this ensure that financial institutions can leverage our award-winning technologies to protect their app code, customer data, and brand reputation with confidence.”
Having successfully deployed Verimatrix XTD app protection for fintech and banking institutions since last year, Risk Associates brings over 20 years of cybersecurity expertise and serves as a trusted MSSP for top brands and startups across the region.
It’s dedication to shielding businesses from the latest threats, including mobile-based attacks, matches well with the opportunity to offer its customers the Verimatrix XTD suite that powerfully protects mobile app owners from reverse engineering, application repackaging attacks, dynamic modification, man-in-the-device attacks while also providing anti-Frida, anti-emulator and anti-debugger defenses.
“Risk Associates welcomes this partnership with Verimatrix to offer proven protections for vital mobile apps that are relied upon by millions in the regions we serve,” said Aziz A. Rahim, Chief Operating Officer at Risk Associates. “Verimatrix’s powerful yet easily-to-implement XTD technologies provide tremendous value to customers through extensive threat visibility and remediation that is often lacking in vulnerable apps that remain crucial for enterprises and their users.”
As part of the XTD Velocity Partner Alliance, Risk Associates now offers the following Verimatrix XTD platform solutions:
Verimatrix XTD Enterprise includes:
- XTD Protect for iOS
- XTD Protect for Android
- XTD Detection & Response
Additional Verimatrix solutions available for resale include:
- XTD Protect for Desktop/Embedded
- XTD Protect for Web
- XTD Protect Native for iOS
- XTD Protect Native for Android
- XTD Managed Services
For more information on joining the Verimatrix XTD Velocity Partner Alliance, visit https://www.verimatrix.com/partners.
About Risk Associates
At Risk Associates, our passion is simplifying compliance for organizations in an increasingly complex regulatory environment. As a UKAS-accredited certification body, we specialize in offering certifications and assessments that enable businesses to meet international standards, minimize risks, and safeguard their operations. We take pride in our role as PCI GEAR (Global Executive Assessor Roundtable) Advisors, ranking among the top 30 QSA companies globally.
Risk Associate’s industry recognition, encompassing PCI DSS, PCI PIN, PCI P2PE, PCI TSP, PCI SSF, PCI SSLC, PCI ASV, PCI 3DS, CSA STAR, SOC I and II, ISO/IEC 27001, ISO/IEC 27701, ISO/IEC 22301, ISO/IEC 20000, HIPAA, HITRUST, GDPR, SWIFT, MARS-E, and NIST, serves as a testament to our expertise, knowledge and compliance competence. As a Qualified Security Assessor (PCI-QSA) company approved by the Payment Card Industry (PCI) Security Standards Council, we are acknowledged as an industry leader specializing in cybersecurity, compliance, information governance, strategy and training. Our services extend across Australia, Europe, the Middle East, Asia Pacific and North America. Visit www.riskassociates.com. Visit www.riskassociates.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319818660/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom